Both Sarepta Therapeutics and Teladoc Health have already cratered, yet the catalysts behind their 2025 collapses—drug-safety black eyes and zero-sum telehealth competition—are still intensifying, making a 2026 dead-cat bounce unlikely.
Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) were two of 2025’s most visible train wrecks, shedding 80 % and 45 % respectively while the Nasdaq climbed. Value hunters are already circling, but the same catalysts that carved out those losses—regulatory red flags for Sarepta and evaporating growth for Teladoc—have not peaked. Until the headlines change, further downside is the path of least resistance.
Sarepta: A Blockbuster Gene Therapy Trapped in a Safety Box
Elevidys, Sarepta’s one-shot DMD gene therapy, was supposed to vault the company past the $2 billion-revenue ceiling. Instead, two post-approval deaths from acute liver failure forced the FDA to slap on a black-box warning and restrict use in non-ambulatory patients—exactly the highest-need, highest-priced cohort.
The fallout was immediate: 2025 revenue guidance was trimmed to $1.86 billion, below 2024’s $1.9 billion, an unheard-of year-over-year decline for a supposed launch window. Management’s attempt to pivot toward earlier-stage candidates hit another wall when a separate gene therapy (SRP-5051) was linked to additional fatal liver events and subsequently shelved.
- No replacement product will reach the market before 2028 at the earliest.
- Label restrictions have compressed average selling price by roughly 18 %, according to channel checks.
- Insurers are now demanding stepped-up post-infusion monitoring, raising cost of goods and deterring centers from adoption.
With Elevidys peak-sales estimates slashed from $3 billion to below $1 billion, SRPT still trades at 6× forward sales—rich for a biotech in reputational free-fall. A dilutive equity raise before 2027 is priced in by most desks, and downside risk to $40–$45 remains if another adverse event surfaces.
Teladoc: The Pandemic Darling That Never Learned to Compete
Teladoc’s 2020 story—virtual visits up 150 %, lock-in contracts with health systems—masked a brittle moat. By 2025, every insurer, hospital chain, and pharmacy had built or white-labeled its own telehealth platform, eroding BetterHelp’s once-sterling growth engine. The unit lost 9 % of its paying members last year while average revenue per user slid 12 %.
Management’s answer has been to chase scale through acquisitions—UpLift, Livongo leftovers, minor international roll-ups—but integration costs have bloated adjusted EBITDA margins from 13 % in 2022 to an expected 4 % in 2026. Revenue growth is now tracking 2 % annually, below U.S. health-care inflation, and net losses have compounded to $14 billion since going public.
Key metrics to watch:
- churn in chronic-care enrollees (already 18 % annualized);
- pricing pressure on BetterHelp subscriptions (ARPU down five straight quarters);
- international revenue mix still under 12 %, too small to offset U.S. decay.
At 1.3× book value the stock screens “cheap,” but ongoing cash burn implies a 2027 liquidity event unless Teladoc can renegotiate its $1.5 billion convertible overhang. Equity upside is capped by that overhang until the firm proves it can grow at GDP-plus rates—something no telehealth pure-play has delivered post-COVID.
What History Says About “Cheap” Health-Care Losers
Since 2010, biotechs that receive black-box warnings within three years of launch underperform the XBI by 34 % over the next 24 months. Telehealth names that post sub-5 % top-line growth after a demand pull-forward trade at an average 1.1× sales—exactly where TDOC sits—yet still lag the sector by 800 bps annually as multiple compression continues.
In short, valuation alone is not a catalyst; operational inflection is. Neither Sarepta nor Teladoc has a credible near-term trigger, and both face binary downside catalysts: another Elevidys safety signal for SRPT, and a covenant breach or convertible dilution for TDOC.
Positioning for 2026: Avoid, Hedge, or Short
- Long-only investors: Skip both names until Phase II safety databases expand (SRPT) or until Teladoc posts two consecutive quarters of organic revenue acceleration above 8 %.
- Active traders: Put-skew in SRPT remains elevated; 20 % out-of-the-money June-26 puts cost 4.8 % versus 3.1 % calls, a low-cost downside hedge if headlines deteriorate.
- Sector rotation: Cash freed from these value traps can be redeployed into large-cap med-tech with pricing power (e.g., Abbott, Medtronic) or profitable rare-disease peers already past their safety cycles.
Bottom line: Until the safety narrative stabilizes for Sarepta and until Teladoc can demonstrate genuine top-line re-acceleration, both stocks remain show-me stories with asymmetric risk to the downside. Patience is expensive; capital is better deployed elsewhere.
Stay ahead of the next market-moving health-care development—bookmark onlytrustedinfo.com for the fastest, most authoritative financial analysis delivered straight when you need it.
